• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AVTX

    Avalo Therapeutics Inc.

    Subscribe to $AVTX
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2015

    Exchange: NASDAQ

    Recent Analyst Ratings for Avalo Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    3/25/2025$36.00Buy
    Stifel
    3/25/2025$23.00Buy
    Jefferies
    2/28/2025$48.00Overweight
    Piper Sandler
    2/21/2025$18.00Outperform
    Wedbush
    12/19/2024$40.00Buy
    BTIG Research
    10/24/2024Neutral
    H.C. Wainwright
    4/16/2024$35.00Perform → Outperform
    Oppenheimer
    3/3/2022$5.00 → $0.75Buy → Hold
    Jefferies
    3/3/2022$5.00 → $4.00Outperform
    RBC Capital
    9/24/2021$6.00Outperform
    RBC Capital Mkts
    See more ratings

    Avalo Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Avalo Therapeutics with a new price target

      Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Avalo Therapeutics with a new price target

      Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Avalo Therapeutics with a new price target

      Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00

      2/28/25 7:19:02 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Avalo Therapeutics with a new price target

      Wedbush initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $18.00

      2/21/25 8:12:21 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Avalo Therapeutics with a new price target

      BTIG Research initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $40.00

      12/19/24 7:28:48 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Avalo Therapeutics

      H.C. Wainwright initiated coverage of Avalo Therapeutics with a rating of Neutral

      10/24/24 6:32:10 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Avalo Therapeutics from Perform to Outperform and set a new price target of $35.00

      4/16/24 7:40:51 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Avalo Therapeutics from Buy to Hold and set a new price target of $0.75 from $5.00 previously

      3/3/22 9:47:08 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital reiterated coverage on Avalo Therapeutics with a new price target

      RBC Capital reiterated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $4.00 from $5.00 previously

      3/3/22 8:10:44 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RBC Capital Mkts initiated coverage on Avalo Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $6.00

      9/24/21 7:16:31 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Avalo Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chan Mitchell converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 8:06:11 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Goldman Jonathan converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:55:44 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Truex Samantha converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:44:14 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kantoff Aaron converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:37:21 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kaplan Gilla converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:30:23 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Almenoff June Sherie converted options into 3,167 shares (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:22:37 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Sullivan Christopher Ryan converted options into 24,200 shares and covered exercise/tax liability with 7,285 shares, increasing direct ownership by 281,917% to 16,921 units (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:11:39 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Neil Garry Arthur converted options into 64,867 shares and covered exercise/tax liability with 17,787 shares, increasing direct ownership by 78,467% to 47,140 units (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      4/1/25 4:01:04 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Heffernan Michael Thomas

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      3/26/25 4:07:47 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Heffernan Michael Thomas

      3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      3/26/25 4:01:16 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Avalo Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      11/14/24 5:21:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Avalo Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

      WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company

      4/30/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics to Participate in Upcoming Investor Conferences

      WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March. TD Cowen 45th Annual Health Care Conference, BostonCorporate PresentationMarch 3, 2025, at 3:10 pm ET Leerink Partners Global Healthcare Conference, Miami 1x1 and small group meetings March 12, 2025 Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available fo

      2/24/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

      WAYNE, Pa. and ROCKVILLE, Md. , Feb. 04, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 10:00 a.m ET. Live webcast and replay can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinic

      2/4/25 8:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

      WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership

      1/2/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

      Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 millionCash runway expected into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement. "We appreciate the outstanding support of our investors by fully exercising their warrants from the private placement earlier this year. While

      11/12/24 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics to Present at Upcoming Investor Conferences

      WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board, will present at two upcoming investor conferences: Stifel 2024 Healthcare Conference, New YorkMonday, November 18, 2024 at 3:35 PM ET Piper Sandler 36th Annual Healthcare Conference, New YorkWednesday, December 5, 2024 at 11:00 AM ET Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archiv

      11/11/24 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates

      Dosed first patient in Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa (HS), with topline data expected in 2026Cash position of approximately $82 million as of September 30, 2024 with subsequent receipt of approximately $58 million of warrant exercise proceeds in 4Q 2024, provides expected runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the third quarter of 2024. "We made significant progress in the third quarter and have dosed the

      11/7/24 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Avalo Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 6:23:00 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 12:05:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avalo Therapeutics Inc.

      SC 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/7/24 5:00:07 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      10/7/24 8:06:58 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      8/23/24 4:34:52 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      8/23/24 4:16:47 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      8/23/24 4:05:24 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      5/13/24 12:38:48 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      4/23/24 2:59:24 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      4/5/24 4:00:56 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Avalo Therapeutics Inc. SEC Filings

    See more
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/8/25 7:02:47 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Avalo Therapeutics Inc.

      DEFA14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:02:41 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Avalo Therapeutics Inc.

      DEF 14A - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/1/25 7:00:42 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      3/26/25 7:01:22 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Avalo Therapeutics Inc.

      10-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      3/20/25 7:06:14 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      3/20/25 7:02:04 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.

      SCHEDULE 13G/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      2/14/25 4:02:30 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      1/13/25 7:07:18 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      1/2/25 7:04:39 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      12/5/24 7:03:53 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Avalo Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

      WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the appointment of Jennifer Riley as Chief Strategy Officer, effective January 1, 2025. In this newly created role, Ms. Riley will oversee corporate strategy and commercial and product pipeline planning, with a goal of driving growth and innovation across the organization. "We are thrilled to welcome Jennifer to Avalo in the newly established role of Chief Strategy Officer," said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. "Jennifer brings extensive leadership

      1/2/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

      -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

      11/4/24 7:30:00 AM ET
      $ATNM
      $AVTX
      $RDHL
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

      WAYNE, Pa. and ROCKVILLE, Md., July 16, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that Mittie Doyle, MD, FACR has joined the Company as its Chief Medical Officer. "We are thrilled to have Mittie join and grow our leadership team at an exciting time as we prepare to initiate our Phase 2 LOTUS Trial in patients with hidradenitis suppurativa. Mittie brings to Avalo a strong combination of drug development experience through all stages of development and exceptional expertise in immunology, rheumatology and dermatology," said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. "Her leadership guided by her robust experience will be invaluable to th

      7/16/24 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

      WAYNE, Pa. and ROCKVILLE, Md., June 24, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced that Paul Varki has joined the Company as its Chief Legal Officer. "We are delighted to have Paul join and grow our leadership team at an exciting time at Avalo following our acquisition and private placement earlier this year," said Garry A. Neil, MD, CEO and Chairman of the Board at Avalo. "Paul's deep industry experience will immediately enhance our strategic and legal competencies. Furthermore, we expect his appointment will augment our ability to create and protect value as well as minimize risk as we progress AVTX-009 in hidradenitis suppurativa and plan for the

      6/24/24 4:01:00 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

      Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a team with expertise spanning finance, business operations, drug discovery and clinical development. "I am honored to announce these additions to our Board of Directors and welcome their operationa

      4/2/24 7:00:00 AM ET
      $AVTX
      $TRML
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

      Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava

      3/27/24 4:01:00 PM ET
      $AVTX
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board

      Avalo's SAB is comprised of key opinion leaders in immunology and the LIGHT-signaling network WAYNE, Pa. and ROCKVILLE, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) announced the appointment of Dr. Michael Croft and Dr. Jeff Edelson to the company's Scientific Advisory Board (SAB). The SAB, which is led by Dr. Carl Ware, provides strategic and scientific guidance to Avalo as it progresses its pipeline of therapies that target the LIGHT-signaling network, notably AVTX-002 (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). Avalo's SAB comprises (biographies below): Carl Ware, Ph.D., Chair of Avalo's SABMichael Croft, Ph.D.Jeff Ed

      5/22/23 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care